Get ready to mark your calendars because the much anticipated third quarter financial results of Intra-Cellular Therapies (NASDAQ: ITCI) are set to be unveiled on Wednesday 30th October 2024. Investors and market watchers will have the chance to dive into the company's financial performance as the announcement is scheduled before market open.
According to financial analysts on Wall Street, the business is likely to announce an estimated per share $0.20 loss for the quarter. Additionally, the company is anticipated to reveal a total revenue of $172.35 million during this period.
The company's full-year performance projections, as provided by Wall Street analysts, suggest a total revenue of $666.57 million. Further, they expect the earnings per share to achieve loss of $0.68 for the fiscal year.
When examining the earnings report from the corresponding quarter of the previous year, it is evident that the company showcased per-share loss of $0.25. This numbers can be credited to the company's total revenue, which amounted to an impressive $126.17 million during the same quarter.
In addition, The firm will review the third quarter financial results on 30th October 2024 at 08:30 AM eastern time, in a conference call with public.
Intra-Cellular Therapies (ITCI) experienced a trading range of $75.57 to $77.05, along with a total volume of 650.90 thousand shares during the day. The stock concluded Monday's regular trading session at $76.82, reflecting an increase of 1.33 percent.
